Entries by

Astex Pharmaceuticals and MD Anderson Announce Strategic Collaboration to Accelerate Clinical Evaluation of Therapies for Patients with Leukemia

8 September 2020 in , /by

Pleasanton, CA, and Houston, TX – September 8th, 2020. ­­– Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, and The University of Texas MD Anderson Cancer Center today announces a  strategic collaboration agreement aimed at accelerating the clinical evaluation of Astex’s pipeline of products for patients with […]

Astex Pharmaceuticals Announces That Tolinapant (ASTX660), a Novel Antagonist of Cellular and X-linked Inhibitors of Apoptosis Proteins, Has Been Granted Orphan Drug Designation for the Treatment of T-cell Lymphomas by the US FDA

31 August 2020 in , /by

Pleasanton, CA, August 31st, 2020. Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd., based in Tokyo, Japan, announces that the US Food & Drug Administration (FDA) has granted orphan drug designation for the company’s novel, orally administered non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP), […]

ASCO Annual Meeting

2 June 2020 in , /by

ASCO Annual Meeting (ASCO will not proceed in person.  The conference will take place using a virtual format. Please visit the ASCO website for more information.) 29 May- 2 June 2020 Chicago, IL visit conference website

Astex Pharmaceuticals announces U.S. Food and Drug Administration (FDA) acceptance for review of an NDA for the combination oral hypomethylating agent cedazuridine and decitabine (ASTX727 or oral C-DEC), for the treatment of MDS and CMML

11 February 2020 in , , /by

NDA is supported by data from the phase 3 ASCERTAIN study of oral C-DEC in adults with intermediate- and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML) FDA designated the application for Priority Review Potential for oral C-DEC to become first approved orally administered hypomethylating agent for MDS and CMML in the U.S. Pleasanton, […]